Cargando…

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gammeltoft, Karen Anbro, Zhou, Yuyong, Ryberg, Line Abildgaard, Pham, Long V., Binderup, Alekxander, Hernandez, Carlos Rene Duarte, Offersgaard, Anna, Fahnøe, Ulrik, Peters, Günther Herbert Johannes, Ramirez, Santseharay, Bukh, Jens, Gottwein, Judith Margarete
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536901/ https://www.ncbi.nlm.nih.gov/pubmed/37766376 http://dx.doi.org/10.3390/v15091970

Ejemplares similares

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
por: Zhou, Yuyong, et al.
Publicado: (2022)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
por: Zhou, Yuyong, et al.
Publicado: (2021)

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
por: Offersgaard, Anna, et al.
Publicado: (2023)

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
por: Pihl, Anne F., et al.
Publicado: (2018)

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2021)

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
por: Ramirez, Santseharay, et al.
Publicado: (2021)

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
por: Lothert, Keven, et al.
Publicado: (2020)

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
por: Underwood, Alexander P., et al.
Publicado: (2023)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
por: Jensen, Sanne Brun, et al.
Publicado: (2019)

Boceprevir
Publicado: (2012)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
por: Czarnota, Anna, et al.
Publicado: (2020)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
por: Fahnøe, Ulrik, et al.
Publicado: (2022)

Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations
por: Tam, Nguyen Minh, et al.
Publicado: (2023)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles
por: Czarnota, Anna, et al.
Publicado: (2023)

High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system
por: Galli, Andrea, et al.
Publicado: (2021)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir
por: Vankadara, Subramanyam, et al.
Publicado: (2022)

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2022)

Boceprevir-induced Herpes Zoster
por: Babalı, Ayşegul, et al.
Publicado: (2018)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
por: Narkhede, Rohan R., et al.
Publicado: (2020)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
por: Mótyán, János András, et al.
Publicado: (2022)

Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1–3 Strains and Does Not Correlate with Virus Replication
por: Galli, Andrea, et al.
Publicado: (2021)

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Acute pancreatitis associated with boceprevir: a case report
por: Bilar, Juliana Miguel, et al.
Publicado: (2014)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ipaq54n0h9kpqlo9nkcskkrmoo